HUTCHMED (China) Ltd
No SEC Form 4 filings for $HCM in the last 30 days.
See all $HCM insider activity →Summit Therapeutics (SMMT) shares rose 10.1% to $16.07 after positive Phase III study results. Snowflake (SNOW) gained 20.6% following better-than-expected earnings. HUTCHMED (HCM) rose 13% after a licensing deal. Tesla (TSLA) increased 5.7% to $377.53. Other stocks like Robinhood (HOOD), Coinbase (COIN), and others also saw gains.
Hutchmed (HCM) secured a licensing deal with GSK (GSK), receiving $110M upfront and up to $1.185B in milestones. Panmure and Cavendish reiterated 'buy' ratings, with target prices of 400p and 370p respectively, citing undervalued oncology pipeline and GSK's validation. Hutchmed's shares rose 15% to 205.84p.
Hutchmed (HCM) secured a $1.3bn licensing deal with GSK for HMPL-A830, receiving $110m upfront. Frontier Developments (FDEV) is developing a Disney IP-based game. Blackbird (BIRD) reported accelerated subscriber growth. Jangada Mines (JAN) investees consider flotations. Futura Medical (FUM) raised £1.6m and launched a sales process, share price fell 24.2%.
Over the past 7 days, alphai's AI scored 5 news stories mentioning HCM (HUTCHMED (China) Ltd). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent HCM coverage spans technology, mergers & acquisitions and earnings.
Deal expands commercial potential outside China.
The deal significantly upgrades Hutchmed's revenue outlook and could drive the stock higher.
Deal economics and global rights transfer should support valuation and near-term sentiment, with development responsibility split by geography.
The deal provides immediate cash ($110 m) and potential milestone payments exceeding $1 billion, likely supporting a sustained price rally.
Approval unlocks a new revenue stream in a high‑need oncology market, likely boosting HUTCHMED's near‑term sales and share price.
alphai scores every news story that mentions HCM with an AI model for sentiment and relevance, and aggregates insider trades from HUTCHMED (China) Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Summit Therapeutics (SMMT) shares rose 10.1% to $16.07 after positive Phase III study results. Snowflake (SNOW) gained 20.6% following better-than-expected earnings. HUTCHMED (HCM) rose 13% after a licensing deal. Tesla (TSLA) increased 5.7% to $377.53. Other stocks like Robinhood (HOOD), Coinbase (COIN), and others also saw gains.
2 min readHutchmed (HCM) secured a licensing deal with GSK (GSK), receiving $110M upfront and up to $1.185B in milestones. Panmure and Cavendish reiterated 'buy' ratings, with target prices of 400p and 370p respectively, citing undervalued oncology pipeline and GSK's validation. Hutchmed's shares rose 15% to 205.84p.
2 min readHutchmed (HCM) secured a $1.3bn licensing deal with GSK for HMPL-A830, receiving $110m upfront. Frontier Developments (FDEV) is developing a Disney IP-based game. Blackbird (BIRD) reported accelerated subscriber growth. Jangada Mines (JAN) investees consider flotations. Futura Medical (FUM) raised £1.6m and launched a sales process, share price fell 24.2%.
4 min readHUTCHMED shares rose 17% after announcing a licensing deal with GSK for its cancer drug HMPL-A830. The agreement is worth up to $1.3 billion, with HUTCHMED receiving $110 million upfront. GSK gains exclusive rights outside Greater China to develop and commercialize the therapy, which targets colorectal, pancreatic, and lung cancers. HUTCHMED will lead initial Phase I trials, with GSK taking over subsequent development.
2 min readHUTCHMED's ATLED® (fanregratinib) received conditional NMPA approval for treating advanced FGFR2-altered intrahepatic cholangiocarcinoma in China. The approval is based on Phase II trial data showing a 42.5% objective response rate. HUTCHMED plans to commercialize the drug, with Phase IIIb trials ongoing.
2 min readPhase 3 SAFFRON trial data reported that osimertinib 80 mg daily plus investigational savolitinib 300 mg twice daily improved progression-free survival and overall survival versus doublet platinum chemotherapy in EGFR-mutated, MET-overexpressed/amplified NSCLC after progression on osimertinib. Safety matched known profiles. AstraZeneca and Hutchmed said full results will be presented later.
4 min readAstraZeneca and HUTCHMED reported SAFFRON Phase III results: Tagrisso (osimertinib) plus Orpathys (savolitinib) improved progression-free survival and overall survival versus doublet platinum chemotherapy in 338 EGFR-mutated NSCLC patients with MET overexpression or amplification who progressed after Tagrisso. Safety matched known profiles, with no new findings. AstraZeneca said the combo aims for a biomarker-directed, all-oral option.
6 min readHutchmed China (HK:0013) shares rose about 5% to HK$20.14 after it reported positive Phase III SAFFRON results for ORPATHYS (savolitinib) plus AstraZeneca’s TAGRISSO (osimertinib) in advanced/metastatic NSCLC with MET-linked tumor changes. The study met progression-free survival and overall survival goals versus platinum chemotherapy, supporting potential broader approvals.
4 min readHUTCHMED shares rose nearly 5% to HK$20.14 after the company reported positive topline results from its SAFFRON Phase III trial. The study of savolitinib (Orpathys) plus osimertinib (Tagrisso) in EGFR-mutant NSCLC met co-primary endpoints, improving progression-free and overall survival in patients with high MET overexpression or amplification after osimertinib progression. The move followed recent analyst target cuts.
2 min readHutchmed (China) said its Phase III trial in EGFR-mutated NSCLC showed improved survival with Orpathys plus AstraZeneca’s Tagrisso compared with standard care, according to the company. The update centers on clinical outcomes that could affect future regulatory and commercial prospects for the therapies.
1 min read
